Efficacy and tolerability after 24 weeks of treatment with telaprevir, pegylated interferon and ribavirin in cirrhotic HIV-HCV coinfected subjects

Miguel Genebat; Francisco Vera; José Hernández-Quero; Pere Domingo; José M. Guardiola; Onofre Martínez-Madrid; Lorena Martínez; Francisco García De La Llana; Jorge Sánchez-Villegas; Hortensia Álvarez; Ana Mariño; José F. Lluch; María A. Martínez-Pérez; Jorge Marín; Ezequiel Ruiz-Mateos; Manuel Leal

doi:10.1016/j.antiviral.2014.01.019

Efficacy and tolerability after 24 weeks of treatment with telaprevir, pegylated interferon and ribavirin in cirrhotic HIV-HCV coinfected subjects

Miguel Genebat, Francisco Vera, José Hernández-Quero, Pere Domingo, José M. Guardiola, Onofre Martínez-Madrid, Lorena Martínez, Francisco García De La Llana, Jorge Sánchez-Villegas, Hortensia Álvarez, Ana Mariño, José F. Lluch, María A. Martínez-Pérez, Jorge Marín, Ezequiel Ruiz-Mateos, Manuel Leal

Department of Medicine

Research output: Contribution to journal › Article › Research › peer-review

6 Citations (Scopus)

Abstract

Efficacy and tolerability of telaprevir, pegylated interferon and ribavirin combination was assessed in 32 cirrhotic genotype 1 hepatitis C (HCV)-HIV coinfected patients. Undetectability of HCV-RNA was observed in 23/32 (71.9%) patients after 24 weeks. Treatment failure was observed in 9/32 subjects: four of them (45.5%) failed triple therapy due to virological rebound, while 5 patients (55.5%) experienced drug-related side effects driving to treatment interruption. These data suggest that telaprevir-containing triple therapy should be considered for treatment of genotype 1 HCV in HIV coinfected patients with liver cirrhosis, although a close vigilance is required because of potential drug-related side effects. © 2014 Elsevier B.V.

Original language	English
Pages (from-to)	59-61
Journal	Antiviral Research
Volume	104
Issue number	1
DOIs	https://doi.org/10.1016/j.antiviral.2014.01.019
Publication status	Published - 1 Apr 2014

Keywords

Hepatitis C virus
HIV
Liver cirrhosis
Telaprevir

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.antiviral.2014.01.019

Cite this

Genebat, M., Vera, F., Hernández-Quero, J., Domingo, P., Guardiola, J. M., Martínez-Madrid, O., Martínez, L., De La Llana, F. G., Sánchez-Villegas, J., Álvarez, H., Mariño, A., Lluch, J. F., Martínez-Pérez, M. A., Marín, J., Ruiz-Mateos, E., & Leal, M. (2014). Efficacy and tolerability after 24 weeks of treatment with telaprevir, pegylated interferon and ribavirin in cirrhotic HIV-HCV coinfected subjects. Antiviral Research, 104(1), 59-61. https://doi.org/10.1016/j.antiviral.2014.01.019

@article{a984bb84e72a46b2869abdc82f635182,

title = "Efficacy and tolerability after 24 weeks of treatment with telaprevir, pegylated interferon and ribavirin in cirrhotic HIV-HCV coinfected subjects",

abstract = "Efficacy and tolerability of telaprevir, pegylated interferon and ribavirin combination was assessed in 32 cirrhotic genotype 1 hepatitis C (HCV)-HIV coinfected patients. Undetectability of HCV-RNA was observed in 23/32 (71.9%) patients after 24 weeks. Treatment failure was observed in 9/32 subjects: four of them (45.5%) failed triple therapy due to virological rebound, while 5 patients (55.5%) experienced drug-related side effects driving to treatment interruption. These data suggest that telaprevir-containing triple therapy should be considered for treatment of genotype 1 HCV in HIV coinfected patients with liver cirrhosis, although a close vigilance is required because of potential drug-related side effects. {\textcopyright} 2014 Elsevier B.V.",

keywords = "Hepatitis C virus, HIV, Liver cirrhosis, Telaprevir",

author = "Miguel Genebat and Francisco Vera and Jos{\'e} Hern{\'a}ndez-Quero and Pere Domingo and Guardiola, {Jos{\'e} M.} and Onofre Mart{\'i}nez-Madrid and Lorena Mart{\'i}nez and {De La Llana}, {Francisco Garc{\'i}a} and Jorge S{\'a}nchez-Villegas and Hortensia {\'A}lvarez and Ana Mari{\~n}o and Lluch, {Jos{\'e} F.} and Mart{\'i}nez-P{\'e}rez, {Mar{\'i}a A.} and Jorge Mar{\'i}n and Ezequiel Ruiz-Mateos and Manuel Leal",

year = "2014",

month = apr,

day = "1",

doi = "10.1016/j.antiviral.2014.01.019",

language = "English",

volume = "104",

pages = "59--61",

journal = "Antiviral Research",

issn = "0166-3542",

publisher = "Elsevier",

number = "1",

}

Genebat, M, Vera, F, Hernández-Quero, J, Domingo, P, Guardiola, JM, Martínez-Madrid, O, Martínez, L, De La Llana, FG, Sánchez-Villegas, J, Álvarez, H, Mariño, A, Lluch, JF, Martínez-Pérez, MA, Marín, J, Ruiz-Mateos, E & Leal, M 2014, 'Efficacy and tolerability after 24 weeks of treatment with telaprevir, pegylated interferon and ribavirin in cirrhotic HIV-HCV coinfected subjects', Antiviral Research, vol. 104, no. 1, pp. 59-61. https://doi.org/10.1016/j.antiviral.2014.01.019

TY - JOUR

T1 - Efficacy and tolerability after 24 weeks of treatment with telaprevir, pegylated interferon and ribavirin in cirrhotic HIV-HCV coinfected subjects

AU - Genebat, Miguel

AU - Vera, Francisco

AU - Hernández-Quero, José

AU - Domingo, Pere

AU - Guardiola, José M.

AU - Martínez-Madrid, Onofre

AU - Martínez, Lorena

AU - De La Llana, Francisco García

AU - Sánchez-Villegas, Jorge

AU - Álvarez, Hortensia

AU - Mariño, Ana

AU - Lluch, José F.

AU - Martínez-Pérez, María A.

AU - Marín, Jorge

AU - Ruiz-Mateos, Ezequiel

AU - Leal, Manuel

PY - 2014/4/1

Y1 - 2014/4/1

N2 - Efficacy and tolerability of telaprevir, pegylated interferon and ribavirin combination was assessed in 32 cirrhotic genotype 1 hepatitis C (HCV)-HIV coinfected patients. Undetectability of HCV-RNA was observed in 23/32 (71.9%) patients after 24 weeks. Treatment failure was observed in 9/32 subjects: four of them (45.5%) failed triple therapy due to virological rebound, while 5 patients (55.5%) experienced drug-related side effects driving to treatment interruption. These data suggest that telaprevir-containing triple therapy should be considered for treatment of genotype 1 HCV in HIV coinfected patients with liver cirrhosis, although a close vigilance is required because of potential drug-related side effects. © 2014 Elsevier B.V.

AB - Efficacy and tolerability of telaprevir, pegylated interferon and ribavirin combination was assessed in 32 cirrhotic genotype 1 hepatitis C (HCV)-HIV coinfected patients. Undetectability of HCV-RNA was observed in 23/32 (71.9%) patients after 24 weeks. Treatment failure was observed in 9/32 subjects: four of them (45.5%) failed triple therapy due to virological rebound, while 5 patients (55.5%) experienced drug-related side effects driving to treatment interruption. These data suggest that telaprevir-containing triple therapy should be considered for treatment of genotype 1 HCV in HIV coinfected patients with liver cirrhosis, although a close vigilance is required because of potential drug-related side effects. © 2014 Elsevier B.V.

KW - Hepatitis C virus

KW - HIV

KW - Liver cirrhosis

KW - Telaprevir

U2 - 10.1016/j.antiviral.2014.01.019

DO - 10.1016/j.antiviral.2014.01.019

M3 - Article

SN - 0166-3542

VL - 104

SP - 59

EP - 61

JO - Antiviral Research

JF - Antiviral Research

IS - 1

ER -

Efficacy and tolerability after 24 weeks of treatment with telaprevir, pegylated interferon and ribavirin in cirrhotic HIV-HCV coinfected subjects

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this